iShares 3 7 Year Treasury Bond ETF vs Viatris Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Viatris Inc for 57 Days on average.
| IEI | VTRS | |
|---|---|---|
Market Cap | $16.72B | $20.03B |
Volume | 3,963,319 | 14,109,977 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $18.27 |
52-Week Low | $113.17 | $9.74 |
Typical Hold Time | 43 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.57 with minimal daily movement (+0.17%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling downward pressure, though oscillators suggest neutral momentum. Recent dividend payments of $0.37-0.38 per share demonstrate consistent shareholder returns. The stock faces headwinds from rising Treasury yields and bond market volatility, which could impact investor appetite for equities.
Outlook remains cautious as higher interest rates and bond market turbulence create challenging conditions. The bearish technical signals and neutral fundamental metrics suggest limited near-term upside potential. Key risks include continued bond market volatility and macroeconomic pressures, though consistent dividend payments provide some defensive characteristics for income-focused investors.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →